Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The druggable genome.

Andrew L Hopkins1, Colin R Groom

  • 1Molecular Informatics, Structure and Design Department, Pfizer Global Research & Development, Sandwich, Kent, CT13 9NJ, UK.

Nature Reviews. Drug Discovery
|September 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Publisher Correction: Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19.

Scientific reports·2021
Same author

Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19.

Scientific reports·2021
Same author

Surveying GPCR solubilisation conditions using surface plasmon resonance.

Analytical biochemistry·2018
Same author

Using more than 801 296 small-molecule crystal structures to aid in protein structure refinement and analysis. Addendum.

Acta crystallographica. Section D, Structural biology·2017
Same author

Using more than 801 296 small-molecule crystal structures to aid in protein structure refinement and analysis.

Acta crystallographica. Section D, Structural biology·2017
Same author

The use of small-molecule structures to complement protein-ligand crystal structures in drug discovery.

Acta crystallographica. Section D, Structural biology·2017
Same journal

p38α inhibition restores axonal transport.

Nature reviews. Drug discovery·2026
Same journal

Inflammatory bowel disease-on-a-chip.

Nature reviews. Drug discovery·2026
Same journal

Designing GPCR-targeted miniproteins.

Nature reviews. Drug discovery·2026
Same journal

Pulsatile FXR agonism.

Nature reviews. Drug discovery·2026
Same journal

CRISPR strategy tackles bacterial toxin.

Nature reviews. Drug discovery·2026
Same journal

Time to peak sales: how long is the climb?

Nature reviews. Drug discovery·2026
See all related articles

Understanding the human genome allows for the identification of potential molecular targets for drug development. This research assesses the number of viable drug targets, crucial for pharmaceutical industry strategies.

Area of Science:

  • Genomics and Bioinformatics
  • Pharmacology and Drug Discovery

Background:

  • The completion of the human genome project provides a foundation for identifying novel therapeutic targets.
  • Strategic development in the pharmaceutical industry relies on understanding the landscape of potential drug targets.

Approach:

  • Assessing the number of molecular targets amenable to therapeutic intervention.
  • Defining the properties of an effective drug and, consequently, a good drug target.

Key Points:

  • The human genome's size offers a vast, yet finite, number of potential molecular targets.
  • Identifying and validating these targets is essential for advancing post-genomic research.
  • Understanding drug properties informs the selection of optimal therapeutic targets.

Related Experiment Videos

Conclusions:

  • A systematic assessment of molecular targets is vital for pharmaceutical research and development.
  • The transition from genomic data to actionable therapeutic strategies requires target identification.
  • Defining criteria for good drug targets streamlines the drug discovery pipeline.